🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,57 USD

Máx. histórico

178,74

2144 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,17%

Rango 52 semanas

14,68 – 24,68

Variación hoy

-7,48%

Cierre anterior

18,99

Rango de hoy

17,44 – 18,92

Volumen hoy

1.859.162

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 16 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/03/2004 18,18 19,14 18,00 18,60 +0,98% 6,27% 68.050
10/03/2004 20,04 20,40 17,40 18,42 -14,96% 14,97% 220.550
09/03/2004 23,16 23,16 21,06 21,66 -5,74% 9,07% 48.150
08/03/2004 22,80 23,28 22,62 22,98 +0,79% 2,89% 40.950
05/03/2004 22,86 22,98 22,50 22,80 +0,26% 2,10% 26.083
04/03/2004 21,60 23,40 21,30 22,74 +7,67% 9,72% 77.350
03/03/2004 21,96 22,14 21,06 21,12 -3,30% 4,92% 22.400
02/03/2004 22,02 22,50 21,18 21,84 -0,27% 5,99% 28.233
01/03/2004 20,58 21,90 20,52 21,90 +6,10% 6,71% 47.333
27/02/2004 20,94 21,60 20,46 20,64 -0,58% 5,44% 42.150
26/02/2004 20,52 21,12 20,40 20,76 +1,17% 3,51% 36.217
25/02/2004 20,58 21,06 20,04 20,52 +0,00% 4,96% 28.533
24/02/2004 22,38 22,38 19,86 20,52 -5,26% 11,26% 97.150
23/02/2004 22,80 23,22 21,60 21,66 -6,96% 7,11% 54.050
20/02/2004 23,58 23,88 22,20 23,28 -0,51% 7,12% 45.433
19/02/2004 23,94 24,30 23,22 23,40 -1,27% 4,51% 47.767
18/02/2004 23,94 24,06 23,16 23,70 +1,02% 3,76% 41.767
17/02/2004 24,00 24,12 22,92 23,46 +2,36% 5,00% 41.517
13/02/2004 23,10 23,40 22,74 22,92 +0,53% 2,86% 28.633
12/02/2004 24,12 24,24 22,80 22,80 -5,00% 5,97% 29.367
11/02/2004 24,00 24,18 23,70 24,00 -0,50% 2,00% 20.017
10/02/2004 23,70 24,30 23,64 24,12 +2,03% 2,78% 47.567
09/02/2004 23,70 23,94 23,16 23,64 +2,07% 3,29% 18.933
06/02/2004 23,52 23,52 22,92 23,16 -1,53% 2,55% 49.067
05/02/2004 22,62 23,58 22,56 23,52 +4,53% 4,51% 34.300
04/02/2004 23,70 24,18 22,50 22,50 -4,58% 7,09% 83.683
03/02/2004 24,30 24,96 23,34 23,58 -2,72% 6,67% 54.567
02/02/2004 24,90 25,44 24,00 24,24 -1,94% 5,78% 54.450
30/01/2004 25,32 25,44 24,60 24,72 -1,44% 3,32% 28.833
29/01/2004 25,80 25,80 24,66 25,08 -1,42% 4,42% 47.633